Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer

被引：3
|
作者：
Moretto, Roberto [1 ,2 ]
Falcone, Alfredo [1 ,2 ]
Cremolini, Chiara [1 ,2 ]
机构：
[1] Univ Pisana, Azienda Osped, Unit Med Oncol 2, Pisa, Italy
[2] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
来源：
INTERNATIONAL JOURNAL OF CANCER | 2020年 / 146卷 / 09期
关键词：
CAPECITABINE;
D O I：
10.1002/ijc.32884
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2652 / 2654
页数：3
相关论文
共 50 条
  • [1] Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer
    Peixoto, Renata D'Alpino
    Kumar, Aalok
    Speers, Caroline
    Renouf, Daniel
    Kennecke, Hagen F.
    Lim, Howard J.
    Cheung, Winson Y.
    Melosky, Barbara
    Gill, Sharlene
    CLINICAL COLORECTAL CANCER, 2015, 14 (01) : 25 - 30
  • [2] Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration
    Cruz, Jan Paolo M.
    Pales, Chris George C.
    Kim, Kwang Min
    Kim, Young Wan
    JOURNAL OF BUON, 2018, 23 (03): : 568 - 573
  • [3] Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis
    Kuang, Ziyu
    Wang, Jiaxi
    Liu, Kexin
    Wu, Jingyuan
    Li, Jie
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (05) : 3030 - 3038
  • [4] The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients
    Kosuke Mima
    Nobutomo Miyanari
    Keisuke Kosumi
    Takuya Tajiri
    Kosuke Kanemitsu
    Toru Takematsu
    Mitsuhiro Inoue
    Takao Mizumoto
    Tatsuo Kubota
    Hideo Baba
    International Journal of Clinical Oncology, 2021, 26 : 903 - 912
  • [5] The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients
    Mima, Kosuke
    Miyanari, Nobutomo
    Kosumi, Keisuke
    Tajiri, Takuya
    Kanemitsu, Kosuke
    Takematsu, Toru
    Inoue, Mitsuhiro
    Mizumoto, Takao
    Kubota, Tatsuo
    Baba, Hideo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (05) : 903 - 912
  • [6] Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
    Hu, Huabin
    Wu, Zehua
    Wang, Chao
    Huang, Yan
    Zhang, Jianwei
    Cai, Yue
    Xie, Xiaoyu
    Li, Jianxia
    Shen, Cailu
    Li, Weiwei
    Ling, Jiayu
    Xu, Xuehu
    Deng, Yanhong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] Impact of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
    Peixoto, Renata D'Alpino
    Kumar, Aalok
    Speers, Caroline
    Renouf, Daniel John
    Kennecke, Hagen F.
    Lim, Howard John
    Cheung, Winson Y.
    Melosky, Barbara L.
    Gill, Sharlene
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
    Yamazaki, K.
    Yamanaka, T.
    Shiozawa, M.
    Manaka, D.
    Kotaka, M.
    Gamoh, M.
    Shiomi, A.
    Makiyama, A.
    Munemoto, Y.
    Rikiyama, T.
    Fukunaga, M.
    Ueki, T.
    Shitara, K.
    Shinkai, H.
    Tanida, N.
    Oki, E.
    Sunami, E.
    Ohtsu, A.
    Maehara, Y.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 (01) : 77 - 84
  • [9] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
    Liao, Leen
    Tang, Jinghua
    Hong, Zhigang
    Jiang, Wu
    Li, Yuan
    Kong, Lingheng
    Han, Kai
    Hou, Zhenlin
    Zhang, Chenzhi
    Zhou, Chi
    Zhang, Linjie
    Sui, Qiaoqi
    Xiao, Binyi
    Mei, Weijian
    Yu, Jiehai
    Yang, Wanjun
    Pan, Zhizhong
    Ding, Pei-Rong
    BMC CANCER, 2024, 24 (01)
  • [10] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
    Leen Liao
    Jinghua Tang
    Zhigang Hong
    Wu Jiang
    Yuan Li
    Lingheng Kong
    Kai Han
    Zhenlin Hou
    Chenzhi Zhang
    Chi Zhou
    Linjie Zhang
    Qiaoqi Sui
    Binyi Xiao
    Weijian Mei
    Jiehai Yu
    Wanjun Yang
    Zhizhong Pan
    Pei-Rong Ding
    BMC Cancer, 24
12345